Skip directly to page options Skip directly to A-Z link
Volume 21, Number 12—December 2015
Synopsis

Opportunistic Pulmonary Bordetella hinzii Infection after Avian Exposure

Aude FabreComments to Author , Clarisse Dupin, François Bénézit, Julien Goret, Caroline Piau, Stéphane Jouneau, Sophie Guillot, Francis Mégraud, Samer Kayal, Benoit Desrues, Alain Le Coustumier, and Nicole Guiso
Author affiliations: Centre Hospitalier de Cahors, Cahors, France (A. Fabre, A. Le Coustumier); Centre Hospitalo-Universitaire de Bordeaux, Bordeaux, France (A. Fabre, J. Goret, F. Mégraud); Centre Hospitalo-Universitaire de Rennes, Rennes, France (C. Dupin, F. Benezit, C. Piau, S. Jouneau, S. Kayal, B. Desrues); Institut Pasteur, Centre National de Référence de la coqueluche et des autres bordetelloses, Paris, France (S. Guillot, N. Guiso)

Main Article

Table

Antimicrobial drug susceptibility testing for human Bordetella hinzii isolates by the Etest method*

Antimicrobial drug Case-patient 1† Case-patient 2† BC-306 (11) BC-305 (11) BL-3210 (3) Hristov et al. isolate 1 (10)‡ Hristov et al. isolate 2 (10)‡ Hristov et al. isolate 3 (10)‡
Amoxicillin ND 32 16§ 16§ 12§ ND ND ND
Amoxicillin/clavulanic acid ND ND 32 16 ND ND ND ND
Ampicillin/sulbactam ND ND 16/8 16/8 ND ND ND ND
Piperacillin 0.38 ND ND ND ND 32 ND ND
Piperacillin/tazobactam 0.25 0.75 1 1 ND ND ND ND
Ticarcillin ND ND ND ND ND >32 >64 ND
Ticarcillin/clavulanic acid ND 32 32 64 ND ND ND ND
Cefoxitine ND >256 ND ND ND ND ND ND
Cefotaxime ND >32 ND ND >32 ND ND ND
Ceftriaxone ND ND 64 64 ND ND ND >32
Ceftazidime 1.5 2 4 4 4 ND ND ND
Cefepime ND 6 8 8 ND >16 >16 >16
Ertapenem 3 0.023 ND ND ND ND ND ND
Imipenem 0.75 1.5 2 2 1 ND ND ND
Meropenem 1 0.125 ND ND ND ≤1 8 4
Doripenem 0.5 0.125 ND ND ND ND ND ND
Aztreonam ND ND ND ND ND >16 >16 ND
Gentamicin 0.75 4 2 4 4 ≤1 4 ≤2
Tobramycin 4 48 ND ND ND >8 >8 4
Amikacin 2 16 ND ND ND 16 ≤4 ≤8
Clarithromycin 4 ND ND ND ND ND ND ND
Clindamycin >256 ND ND ND ND ND ND ND
Rifampin 1 >32 N ND ND ND ND ND
Levofloxacin >32 0.25 2 2 ND ND ND ND
Ciprofloxacin >32 0.75 4 4 >32 >2 >2 >2
Moxifloxacin 4 0.5 ND ND ND ND ND ND
Cotrimoxazole 0.38 ND 0.047 0.023 ND ≤0.5/9.5 2/38 ND
Vancomycin >32 >256 ND ND ND ND ND ND
Teicoplanin >32 >256 ND ND ND ND ND ND
Daptomycine >256 >256 ND ND ND ND ND ND
Linezolid >256 >256 ND ND ND ND ND ND
Fusidic acid >32 ND ND ND ND ND ND ND
Tetracycline ND ND ND ND 0.38 ND ND ND
Minocycline 1 ND ND ND ND ≤2 >8 ND
Tigecycline 0.5 0.38 ND ND ND ND ND ND
Colistin 0.38 0.094 ND ND ND ND ND ND
Fosfomycine >1024 >1024 ND ND ND ND ND ND

*Values are MICs as determined by Etest in μg/mL ND, not determined.
†This study.
‡Isolates 1, 2, and 3 of Hristov et al. case correspond to respiratory isolates (1 and 2) and blood isolate (isolate 3).
§Ampicillin rather than amoxicillin was tested.

Main Article

References
  1. Register  KB, Kunkle  RA. Strain-specific virulence of Bordetella hinzii in poultry. Avian Dis. 2009;53:50–4. DOIPubMedGoogle Scholar
  2. Jiyipong  T, Morand  S, Jittapalapong  S, Raoult  D, Rolain  JM. Bordetella hinzii in rodents, Southeast Asia. Emerg Infect Dis. 2013;19:502–3. DOIPubMedGoogle Scholar
  3. Arvand  M, Feldhues  R, Mieth  M, Kraus  T, Vandamme  P. Chronic cholangitis caused by Bordetella hinzii in a liver transplant recipient. J Clin Microbiol. 2004;42:2335–7. DOIPubMedGoogle Scholar
  4. Cookson  BT, Vandamme  P, Carlson  LC, Larson  AM, Sheffield  JV, Kersters  K, Bacteremia caused by a novel Bordetella species, “B. hinzii. J Clin Microbiol. 1994;32:2569–71 .PubMedGoogle Scholar
  5. Funke  G, Hess  T, von Graevenitz  A, Vandamme  P. Characteristics of Bordetella hinzii strains isolated from a cystic fibrosis patient over a 3-year period. J Clin Microbiol. 1996;34:966–9 .PubMedGoogle Scholar
  6. Register  KB, Sacco  RE, Nordholm  GE. Comparison of ribotyping and restriction enzyme analysis for inter- and intraspecies discrimination of Bordetella avium and Bordetella hinzii. J Clin Microbiol. 2003;41:1512–9. DOIPubMedGoogle Scholar
  7. Hayashimoto  N, Morita  H, Yasuda  M, Ishida  T, Kameda  S. Takakura A, et al. Prevalence of Bordetella hinzii in mice in experimental facilities in Japan. Res Vet Sci. 2012;93:624–6.
  8. Vandamme  P, Hommez  J, Vancanneyt  M, Monsieurs  M, Hoste  B. Cookson B, et al. Bordetella hinzii sp. nov., isolated from poultry and humans. Int J Syst Bacteriol. 1995;45:37–45.
  9. Fry  NK, Duncan  J, Edwards  MT, Tilley  RE, Chitnavis  D, Harman  R, A UK clinical isolate of Bordetella hinzii from a patient with myelodysplastic syndrome. J Med Microbiol. 2007;56:1700–3. DOIPubMedGoogle Scholar
  10. Hristov  AC, Auwaerter  PG, Romagnoli  M, Carroll  KC. Bordetella hinzii septicemia in association with Epstein-Barr virus viremia and an Epstein-Barr virus–associated diffuse large B-cell lymphoma. Diagn Microbiol Infect Dis. 2008;61:484–6. DOIPubMedGoogle Scholar
  11. Kattar  MM, Chavez  JF, Limaye  AP, Rassoulian-Barrett  SL, Yarfitz  SL, Carlson  LC, Application of 16S rRNA gene sequencing to identify Bordetella hinzii as the causative agent of fatal septicemia. J Clin Microbiol. 2000;38:789–94 .PubMedGoogle Scholar
  12. Spilker  T, Liwienski  AA. LiPuma JJ. Identification of Bordetella spp. in respiratory specimens from individuals with cystic fibrosis. Clin Microbiol Infect. 2008;14:504–6. DOIPubMedGoogle Scholar
  13. Gadea  I, Cuenca-Estrella  M, Benito  N, Blanco  A, Fernandez-Guerrero  ML, Valero-Guillen  PL, Bordetella hinzii, a “new” opportunistic pathogen to think about. J Infect. 2000;40:298–9. DOIPubMedGoogle Scholar
  14. Palacián Ruiz  MP, Vasquez Martinez  MA, Lopez Calleja  AI. Respiratory infection caused by Bordetella hinzii. Arch Bronconeumol. 2013;49:409–10 .PubMedGoogle Scholar
  15. Degand  N, Carbonnelle  E, Dauphin  B, Beretti  JL, Le Bourgeois  M, Sermet-Gaudelus  I, Matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of nonfermenting gram-negative bacilli isolated from cystic fibrosis patients. J Clin Microbiol. 2008;46:3361–7. DOIPubMedGoogle Scholar
  16. Le Coustumier  A, Njamkepo  E, Cattoir  V, Guillot  S, Guiso  N. Bordetella petrii infection with long-lasting persistence in human. Emerg Infect Dis. 2011;17:612–8. DOIPubMedGoogle Scholar
  17. Pritt  B, O'Brien  L, Winn  W. Mucoid Pseudomonas in cystic fibrosis. Am J Clin Pathol. 2007;128:32–4. DOIPubMedGoogle Scholar

Main Article

Page created: November 12, 2015
Page updated: November 12, 2015
Page reviewed: November 12, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external